Endo, Inc. (NDOI)
OTCMKTS · Delayed Price · Currency is USD
21.25
+0.26 (1.22%)
Jul 17, 2025, 9:30 AM EDT
Endo, Inc. Revenue
Endo, Inc. had revenue of $392.83M in the quarter ending March 31, 2025, a decrease of -6.36%. This brings the company's revenue in the last twelve months to $1.73B, down -9.52% year-over-year. In the year 2024, Endo, Inc. had annual revenue of $1.76B, down -12.50%.
Revenue (ttm)
1.73B
Revenue Growth
-9.52%
P/S Ratio
0.94
Revenue / Employee
556.31K
Employees
3,116
Market Cap
1.62B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.76B | -251.38M | -12.50% |
Dec 31, 2023 | 2.01B | -307.36M | -13.25% |
Dec 31, 2022 | 2.32B | -674.33M | -22.53% |
Dec 31, 2021 | 2.99B | 90.13M | 3.10% |
Dec 31, 2020 | 2.90B | -11.29M | -0.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
BioStem Technologies | 332.45M |
Endo, Inc. News
- 1 day ago - Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc. - PRNewsWire
- 4 days ago - Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025 - Business Wire
- 4 days ago - Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025 - Business Wire
- 4 days ago - OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 - GlobeNewsWire
- 24 days ago - Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025 - Business Wire
- 4 weeks ago - Endo Completes International Pharmaceuticals Business Divestiture - PRNewsWire
- 5 weeks ago - Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader - PRNewsWire
- 5 weeks ago - Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company - PRNewsWire